Vera Therapeutics, Inc.
VERA
$39.96
-$1.21-2.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 27.08% | 25.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.24% | 4.73% | |||
| Operating Income | -12.24% | -4.73% | |||
| Income Before Tax | -13.45% | -4.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.46% | -4.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.46% | -4.92% | |||
| EBIT | -12.24% | -4.73% | |||
| EBITDA | -12.25% | -4.72% | |||
| EPS Basic | -10.38% | -4.83% | |||
| Normalized Basic EPS | -10.14% | -4.83% | |||
| EPS Diluted | -10.38% | -4.83% | |||
| Normalized Diluted EPS | -10.14% | -4.83% | |||
| Average Basic Shares Outstanding | 2.79% | 0.09% | |||
| Average Diluted Shares Outstanding | 2.79% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||